These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 36770965)

  • 1. A Novel Approach to Develop New and Potent Inhibitors for the Simultaneous Inhibition of Protease and Helicase Activities of HCV NS3/4A Protease: A Computational Approach.
    Riaz M; Rehman AU; Waqas M; Khalid A; Abdalla AN; Mahmood A; Hu J; Wadood A
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico identification and evaluation of leads for the simultaneous inhibition of protease and helicase activities of HCV NS3/4A protease using complex based pharmacophore mapping and virtual screening.
    Wadood A; Riaz M; Uddin R; Ul-Haq Z
    PLoS One; 2014; 9(2):e89109. PubMed ID: 24551230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
    El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
    Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Molecular recognition mechanism and motion of HCV NS3/4A protease with Faldaprevir analogue].
    Liang L; Hu J; Du W; Zuo K; Liu W; Gou X
    Sheng Wu Gong Cheng Xue Bao; 2016 May; 32(5):669-682. PubMed ID: 29019204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of potential inhibitors for HCV NS3 genotype 4a by combining protein-ligand interaction fingerprint, 3D pharmacophore, docking, and dynamic simulation.
    El-Hasab MAE; El-Bastawissy EE; El-Moselhy TF
    J Biomol Struct Dyn; 2018 May; 36(7):1713-1727. PubMed ID: 28531373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the structural and energetic basis of inhibitor and substrate bound to the full-length NS3/4A: insights from molecular dynamics simulation, binding free energy calculation and network analysis.
    Xue W; Wang M; Jin X; Liu H; Yao X
    Mol Biosyst; 2012 Oct; 8(10):2753-65. PubMed ID: 22833015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computational study on the inhibitor binding mode and allosteric regulation mechanism in hepatitis C virus NS3/4A protein.
    Xue W; Yang Y; Wang X; Liu H; Yao X
    PLoS One; 2014; 9(2):e87077. PubMed ID: 24586263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of interactions between the hepatitis C virus NS3/4A and sulfonamidobenzamide based molecules using molecular docking, molecular dynamics simulations and binding free energy calculations.
    Ren J; Vaid TM; Lee H; Ojeda I; Johnson ME
    J Comput Aided Mol Des; 2023 Jan; 37(1):53-65. PubMed ID: 36427108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions of ketoamide inhibitors on HCV NS3/4A protease target: molecular docking studies.
    Wadood A; Riaz M; Jamal SB; Shah M
    Mol Biol Rep; 2014 Jan; 41(1):337-45. PubMed ID: 24234753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A macrocyclic HCV NS3/4A protease inhibitor interacts with protease and helicase residues in the complex with its full-length target.
    Schiering N; D'Arcy A; Villard F; Simic O; Kamke M; Monnet G; Hassiepen U; Svergun DI; Pulfer R; Eder J; Raman P; Bodendorf U
    Proc Natl Acad Sci U S A; 2011 Dec; 108(52):21052-6. PubMed ID: 22160684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis.
    Xue W; Ban Y; Liu H; Yao X
    J Chem Inf Model; 2014 Feb; 54(2):621-33. PubMed ID: 23745769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C Virus NS3/4A Inhibition and Host Immunomodulation by Tannins from
    Patil VS; Harish DR; Vetrivel U; Roy S; Deshpande SH; Hegde HV
    Molecules; 2022 Feb; 27(3):. PubMed ID: 35164341
    [No Abstract]   [Full Text] [Related]  

  • 13. A comparative study of the efficiency of HCV NS3/4A protease drugs against different HCV genotypes using in silico approaches.
    Ezat AA; Elshemey WM
    Life Sci; 2019 Jan; 217():176-184. PubMed ID: 30528183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacophore-Assisted Covalent Docking Identifies a Potential Covalent Inhibitor for Drug-Resistant Genotype 3 Variants of Hepatitis C Viral NS3/4A Serine Protease.
    Iman K; Mirza MU; Sadia F; Froeyen M; Trant JF; Chaudhary SU
    Viruses; 2024 Aug; 16(8):. PubMed ID: 39205224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular docking investigation of the binding interactions of macrocyclic inhibitors with HCV NS3 protease and its mutants (R155K, D168A and A156V).
    Ezat AA; El-Bialy NS; Mostafa HI; Ibrahim MA
    Protein J; 2014 Feb; 33(1):32-47. PubMed ID: 24374429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low susceptibility of asunaprevir towards R155K and D168A point mutations in HCV NS3/4A protease: A molecular dynamics simulation.
    Kammarabutr J; Mahalapbutr P; Nutho B; Kungwan N; Rungrotmongkol T
    J Mol Graph Model; 2019 Jun; 89():122-130. PubMed ID: 30884449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle.
    McGivern DR; Masaki T; Lovell W; Hamlett C; Saalau-Bethell S; Graham B
    J Virol; 2015 May; 89(10):5362-70. PubMed ID: 25740995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors.
    Dultz G; Shimakami T; Schneider M; Murai K; Yamane D; Marion A; Zeitler TM; Stross C; Grimm C; Richter RM; Bäumer K; Yi M; Biondi RM; Zeuzem S; Tampé R; Antes I; Lange CM; Welsch C
    J Biol Chem; 2020 Oct; 295(40):13862-13874. PubMed ID: 32747444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors.
    Matthew AN; Zephyr J; Nageswara Rao D; Henes M; Kamran W; Kosovrasti K; Hedger AK; Lockbaum GJ; Timm J; Ali A; Kurt Yilmaz N; Schiffer CA
    mBio; 2020 Mar; 11(2):. PubMed ID: 32234812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrocyclic Hepatitis C Virus NS3/4A Protease Inhibitors: An Overview of Medicinal Chemistry.
    Pillaiyar T; Namasivayam V; Manickam M
    Curr Med Chem; 2016; 23(29):3404-3447. PubMed ID: 27160539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.